| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.098 | 0.004 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.004 |